Supratarsal Injection of Triamcinolone for Vernal Keratoconjunctivitis

Muhammad Rashad Qamar, Ejaz Latif, Tariq Mahmood Arain, Ehsan Ullah

Pak J Ophthalmol 2010, Vol. 26 No. 1

See end of article for authors affiliations	Purpose: To find out safety and effectiveness of supratarsal injection of Triamcinolone in Vernal Keratoconjunctivitis (VKC).
	Material and Methods: This study was conducted from 1 st February 2006 to 15 th July 2007 in Department of Ophthalmology BVH, Bahawalpur. Eight hundred
Correspondence to: Rao Muhammad Rashad Qamar 29-B, Medical Colony, Bahawalpur.	and eighty eyes of 440 diagnosed patients of VKC, of either sex and all ages were included in the study. Patients with raised IOP, post-herpetic corneal scar, tightly closed eyelids were excluded from the study. It was a prospective, uncontrolled trial. The patients were enrolled and given the first supratarsal injection of Triamcinolone. Their record was maintained and all the patients were followed up for obtaining the data about effectiveness and side effects of therapy.
	Results: We treated 880 eyes of 440 patients, out of which 81.82% were males. Mean age was 16 years (Range: 2—42 years). All of the patients had itching of eyes and the rest of the clinical features were redness, cobble-stone papillae and Tranta's dots. Mean duration of disease was 18 weeks (Range: 4 weeks to 6 months). Patients were followed up and multiple injections were given to control the disease. Transient redness was most common among the side effects of injection therapy. Study shows 100% effectiveness of supratarsal injection of Triamcinolone acetonide in VKC although recurrence was seen.
Received for publication April' 2009	Conclusions: Supratarsal injection of Triamcinolone is safe, cost-effective and simple way of management of VKC. Curative treatment for VKC still remains elusive.

KC is a bilateral, recurrent, interstitial inflammation of the conjunctiva¹ which affects children and young adults². About 1- 2.5% of ophthalmology visits in outpatient clinics have VKC3,4. More than 80% of patients are below 18 years of age⁵. Boys are affected twice more than girls⁶. Wide range of therapeutic modalities are currently available for the treatment of VKC. Most of the patients show mild symptoms, usually relieved by over the counter medication. More severe cases may need topical nonsteroidal anti inflammatory drugs (NSAID), or topical steroids, mast cell stabilizers, or even oral steroids and cyclosporin. More recently, topical ketotifen fumarate, mipragoside levocabastatine hydrochloride, lodoxamide tromethamine, excimer laser, and surgical therapy have also been used⁷⁻¹¹.

However, most of these newer treatment modalities have been found relatively ineffective. Systemic therapy with high doses of aspirin relieve some signs and symptoms, but tarsal cobblestone papillae and shield ulcers remain relatively unaffected¹². More recently, successful use of supratarsal injection of corticosteroids has been reported in severe and refractory VKC^{13,14}.

Triamcinolone is one of the effective corticosteroid in VKC and its role in ocular therapeutics is increasing day by day¹⁵. We have conducted this study to find out safety and effectiveness of supratarsal injection of Triamcinolone in VKC. We also made an attempt to gauge its effectiveness by the age of the patient and by the severity and the duration of disease.

MATERIAL AND METHODS

This study was conducted from 1st February 2006 to 15th July 2007 in Department of Ophthalmology BVH, Bahawalpur. Eight hundred and eighty eyes of 440 diagnosed patients of VKC, of either sex and all ages were included in the study. Patients with raised IOP post-herpetic corneal scar and tightly closed eyelids were excluded from the study.

It was a prospective, uncontrolled trial. The patients were enrolled and given the first supratarsal injection of Triamcinolone. Their record was maintained and all the patients were followed up for obtaining the data about effectiveness and side effects of therapy. Following procedure of supratarsal injection was adopted as shown in Fig. 1-7.



Fig. 1



Fig. 2.



Fig. 3.



Fig. 4.



Fig. 5.



Fig. 6.



Fig. 7.




Fig 8: Sex distribution




Fig. 9: Age distribution




Fig 10: Results

- Every patient was explained about the course of treatment.
- Informed consent was taken.
- Conjunctiva was anesthetized with Proparacaine 0.5% eye drops.
- Upper eyelid was everted.
- One ml syringe with 26 gauge needle was used.
- Patient was asked to look down.
- Needle was inserted through conjunctiva.

- One ml of Triamcinolone acetonide 40 mg/ml (Kenacortr A) was injected.
- Pressure by pad was applied for 2 to 3 minutes.
- Topical combination drops were then instilled.

RESULTS

Mean duration of disease was 18 weeks (Range: 4 weeks to 6 months). Patients were asked for follow up visits after 1 day, 1 week, 1 month, 6 months and 1 year. Injection was repeated at 24 to 72 hours on recurrence of symptoms. Multiple injections were given to control the disease. Repeat injections were given 4 to 12 months apart (average 4). Duration between repeat injections was more in patients who avoided rubbing and sunlight.

Transient redness was most common among the side effects of injection therapy.

DISCUSSION

VKC has got wide geographical distribution. It is more common in teenagers, especially boys. Mostly it presents mild symptoms and does not attract much attention of either patient or the doctor. But severe symptoms are really disturbing to the patient as well as treatment of severe VKC is a difficult problem for the ophthalmologist¹⁶ because these patients develop disease related and/or iatrogenic complications. Wide range of therapeutic modalities are currently available for the treatment of VKC. Topical nonsteroidal anti inflammatory drugs (NSAID), or topical steroids, mast cell stabilizers, or even oral steroids and cyclosporin have been used previously. More recently, topical ketotifen fumarate, mipragoside levocabastatine hydrochloride, lodoxamide tromethamine, excimer laser, and surgical therapy have also been used7-11. Holsclaw et al¹³ reported successful use of supratarsal injection of steroid in VKC. Saini et al14 also observed similar results. Satvir Singh studied the effectiveness and side effects of supratarsal injection of steroids and labelled it as safe therapy⁵. Recent studies have also shown that Triamcinolone is equally effective than any other corticosteroid given as supratarsal injection^{14,16}.

Our study shows its 100% effectiveness although it needed multiple injections. Response was independent of age of the patient and of the severity and duration of disease. Side effects were infrequent and well tolerable. Recurrence was seen in all cases.

Although Triamcinolone given as a supratarsal injection is effective in severe VKC yet as we have seen in this study that VKC recurred in all cases. So the

curative treatment for VKC is still elusive. It needs further experimentation and research on the subject.

CONCLUSIONS

- Supratarsal injection of Triamcinolone is safe, costeffective and simple way of management of VKC.
- It is worth-considering in patients with poor compliance to drugs and those showing side effects/complications.
- Curative treatment for VKC still remains elusive.

Author's affiliation

Muhammad Rashad Qamar Assistant Professor Department of Ophthalmology QAMC & BVH Bahawalpur

Prof. Ejaz Latif Department of Ophthalmology QAMC & BVH Bahawalpur

Dr. Tariq Mahmood Arain Associate Professor Department of Ophthalmology QAMC & BVH Bahawalpur

Dr. Ehsan Ullah Department of Ophthalmology QAMC, Bahawalpur

REFERENCE

1. **Theodre FH, Schlossnan A.** Vernal conjunctivitis. In: Ocular Allergy. Baltimore: Waverly Press Inc. 1958; 98-137.

- Javadi M. Focal points in treatment of vernal keratoconjunctivitis [in Persian]. Bina J Ophthalmol (Supplement). 1996; 4: 14-5.
- 3. **Bagheri A, Khaksar M.** Epidemiology of vernal keratoconjunctivitis in Kashan [in Persian]. Feiz. 1996; 2: 34-52.
- 4. Allansmith MR. Vernal Conjunctivitis: Duane's Clinical Ophthalmology. Philadelphia: Lippincot-Raven; 1991; 4: 1-8.
- Singh S, Pal V, Dhull CS. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Ind J Ophthalmol. 2001; 49: 241-5.
- 6. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol. 1986; 30: 229-44.
- Fujishima H, Fukagawa K, Satake Y, et al. Combined medical and surgical treatment of server vernal keratoconjunctivitis. Jpn J Ophthalmol. 2000; 44: 511–5.
- Verin PH, Dicker ID, Mortemousque B. Nedo cromil sodium eye drops are more effective than sodium cromoglycate eye drops for long-term management of vernal keratoconjunctivitis. Clin Exp Allergy. 1999; 2: 529-36.
- Cameron JA, Antonios SR, Badr IA. Excimer laser phototherapeutic keratectomy for shield ulcers and corneal plaques in vernal keratoconjunctivitis. J Refract Cataract Surg. 1995; 11: 31-5.
- 10. Sud RN, Greval RS, Bajwa RS. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J Med Sci. 1995; 49: 205-9.
- 11. **Mendicute J, Aranzasti C, Eder F, et al.** Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis. Eye. 1997; 11: 75-8.
- 12. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol. 1983; 95: 502-5.
- 13. Holsclaw DS, Witcher JP, Wong IG, et al. Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol. 1996; 121: 243-49.
- 14. Saini JS, Gupta A, Pandey SK, et al. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand. 1999; 77: 515-8.
- 15. Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone in ocular therapeutics. Surv Ophthalmol. 2007; 52: 503-22.
- 16. Aghadoost D, Zare M. Supratarsal injection of Triamcinolone acetonide in the treatment of refractory vernal keratoconjunctivitis. Arch Ira Med. 2004; 7: 41-3.